1. P1114: ZANDELISIB ON INTERMITTENT DOSING AS A SINGLE AGENT OR IN COMBINATION WITH RITUXIMAB OR ZANUBRUTINIB IN RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): RESULTS FROM A MULTI-ARM PHASE 1B STUDY. (23rd June 2022) Authors: Soumerai, J. D.; Jagadeesh, D.; Salman, H.; Samaniego, F.; Patel, K.; Stathis, A.; Reddy, N.; Kenkre, V. P.; Asch, A.; Diefenbach, C.; Lossos, I. S.; Persky, D.; Awan, F.; Huang, W.; Vandever, K.; Zelenetz, A. D. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1004 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P1190: OUTCOMES BY BCL2 AND MYC EXPRESSION AND REARRANGEMENTS IN UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA FROM THE POLARIX TRIAL. (23rd June 2022) Authors: Morschhauser, F.; Jiang, Y.; Jardin, F.; Herrera, A. F.; Sehn, L. H.; Herbaux, C.; Flowers, C.; Phillips, T.; López Guillermo, A.; Diefenbach, C.; Gregory, G. P.; Kim, A.; Barbui, A. M.; Balasubramanian, S.; Harris, W.; Hirata, J.; Paulson, J. N.; Lee, C.; Lenz, G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1076 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. POLATUZUMAB VEDOTIN (POLA) + OBINUTUZUMAB (G) + LENALIDOMIDE (LEN) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL): PHASE IB/II INTERIM ANALYSIS. (12th June 2019) Authors: Diefenbach, C.; Kahl, B.; Banerjee, L.; McMillan, A.; Ramchandren, R.; Miall, F.; Briones, J.; Cordoba, R.; Gonzalez‐Barca, E.; Panizo, C.; Hirata, J.; Chang, N.; Musick, L.; Abrisqueta, P. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 175 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗